Investorsmay be trackingfundamental and technical data for Interleukin Genetics, Inc. (OTCPK:ILIU). The company has a current Value Composite Score of 100. Using a scale from 0 to 100, a lower score would represent an undervalued company and a higher score would indicate an expensive or overvalued company. This ranking was developed by James OShaughnessy using six different valuation ratios including price to book value, price to sales, EBITDA to EV, price to cash flow, price to earnings, and shareholder yield.

Shifting the focus to some ROIC (Return on Invested Capital) numbers, Interleukin Genetics, Inc. (OTCPK:ILIU)s ROIC is -15.844075. The ROIC 5 year average is -8.915091 and the ROIC Quality ratio is -0.849448. ROIC is a profitability ratio that measures the return that an investment generates for those providing capital. ROIC helps show how efficient a company is at turning capital into profits. ROIC may be a good measure to view when examining whether or not a company is able to invest wisely. ROIC may also be an important metric for the value investor who is trying to determine the companys moat.

Traders may also be following some financial ratios for Interleukin Genetics, Inc. (OTCPK:ILIU). Currently, the firm has a Gross Margin (Marx) ratio of 0.191377. This number is based off of the research by University of Rochester professor Robert Novy-Marx. Marx believed that a high gross income ratio was a sign of a quality company. Looking further, Interleukin Genetics, Inc. has a Gross Margin score of 5. This score is based on the Gross Margin (Marx) metric using a scale from 1 to 100 where a 1 would be seen as positive, and a 100 would be regarded as negative. Investors may also be paying increased attention to the EV for Interleukin Genetics, Inc. (OTCPK:ILIU). The company currently has an EV or Enterprise Value of 19196. The EV helps show how the market assigns value to a company as a whole. EV is a modification of market cap, as it incorporates debt and cash for assessing a firms valuation. Watching a firms EV may be useful when comparing companies with different capital structures. EV can help investors gain a truer sense of whether a company is undervalued or not.Interested investors may be looking at the Magic Formula (MF Rank) on shares of Interleukin Genetics, Inc. (OTCPK:ILIU). Currently, the company has an MF Rank of 17026. Successful hedge fund manager Joel Greenblatt developed the Magic Formula which was introduced in his book The Little Book That Beats the Market. Greenblatt was focused on a method for identifying bargains when purchasing company shares. This included spotting companies that earn more relative to the stock price, or companies with a high earnings yield. The Magic Formula may help spot good, healthy companies. The MF is calculated using earnings yield and ROIC ratios. In general, investors may be searching for stocks with the lowest combined MF Rank.

Continued here:
Stock Concentration on Shares of Interleukin Genetics, Inc. (OTCPK:ILIU) - Lenox Ledger

The Genetics Society of America (GSA), founded in 1931, is the professional membership organization for scientific researchers and educators in the field of genetics. Our members work to advance knowledge in the basic mechanisms of inheritance, from the molecular to the population level.

Online ISSN: 1943-2631

Read the original:
Genetics - Official Site

Cancer Genetics, Inc. Announces 15% Revenue Increase in First Quarter of 2017 over 2016 on Strong Organic Growth While Continuing on Path to Profitability

RUTHERFORD, N.J. and LOS ANGELES, May 11, 2017 -- Cancer Genetics, Inc. (Nasdaq:CGIX), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced today financial and operating results for the first quarterended March 31, 2017.

We are continuing to scale our revenue while making significant operational improvements as we execute on our vision to become the preeminent oncology diagnostics partner for biopharma companies, cancer centers and clinicians,said Panna Sharma, CEO and President of Cancer Genetics, Inc.We are growing market share in an industry undergoing a major transformation in its approach to oncology therapeutics development, clinical trials and patient monitoring. As the industry embraces precision medicine and individualized testing to drive higher standards of patient treatment and disease management, CGI is emerging as the diagnostic and testing partner of choice for biopharma companies, cancer centers and clinicians. Our team is actively working with 9 of the top 10 and 16 of the top 20 biopharma companies where we are providing critical molecular information and testing to help with clinical trials and in many cases developing innovative new tests and technologies to help improve patient diagnosis and monitoring.

The commitment we made to have the most comprehensive capabilities in oncology diagnostics continues with our launch into hereditary cancers with Focus::HERSite, further development into immuno-oncology through our Complete::IO panel, and the launch of our first liquid biopsy test, Liquid::Lung-cfDNA. Additionally, our partnerships to leverage artificial intelligence for clinical trial matching and drug development, is more evidence that we are building a leading and durable brand in precision oncology diagnostics. Our comprehensive, disease-focused oncology testing portfolio continues to grow, and covers 9 of the top 10 cancers, while we attract new clinical customers and deepen our relationships and projects with biopharma companies globally, continued Sharma.

FINANCIAL HIGHLIGHTS FOR THE QUARTER

Our efforts to drive revenue growth while improving operating efficiencies continues to accelerate, commented Sharma. Total operating expenses were reduced another 14% sequentially when compared to Q4 2016, and our loss from operations declined 46% from compared to Q1 2016, moving us closer to profitability. While net loss on a GAAP basis increased year-over-year to due to certain accounting treatment, its important to note that $7.5 million of the loss is related to non-cash charges from the change in fair value of derivative instruments. Quarter to quarter, these non-cash charges related to changes in our stock price may fluctuate significantly and impact GAAP net income and earnings per share.

FIRST QUARTER AND RECENT BUSINESS HIGHLIGHTS

The company reported total revenue of $7.0 million for the first quarter, compared to $6.1 million in Q1 2016, an increase of 15% year-over-year, driven by organic growth across all market categories: biopharma, clinical and discovery.

Revenue from biopharma partners and customers increased 11% to $3.7 million in the first quarter, compared to $3.4 million during Q1 2016. Additionally, the company increased the number of clinical studies and trials it is supporting to 140, up 12% from Q4 2016.

Clinical services revenue increased 20% in the first quarter of 2017 over the same period in 2016, from $2.5 million to $3.0 million. The growth was driven by an increase in clinical test volumes from 10,327 in Q1 2016 to 12,310 in the first quarter of 2017, an increase of 19%.

Discovery services contributed an additional $293 thousand in revenue for the first quarter of 2017, a 12% increase over Q1 2016, driven by significant demand for discovery solutions by research institutions where next-generation sequencing is combined with novel bioinformatics analysis. Discovery services, mostly performed in India, provides genomic and bioinformatics support for global discovery and pre-clinical initiatives.

Sharma continued, Our first quarter was marked by several important achievements and milestones. Were very pleased with the CLIA approval of our high performance next-generation immuno-oncology assay, Complete::IO, which meets the need for our customers to better monitor and stratify patient populations during immuno-oncology and immune therapy clinical trials, with the simultaneous detection of up to 10 markers on each cell. We also continue to gain traction on our solid tumor liquid biopsy testing platform with Liquid::Lung-cfDNA, which increases our ability to attract new customers and better service existing clients. The market for liquid biopsy solid tumor testing is expected to reach $20 billion by 2020. We are well positioned to capture market share. Given these market dynamics, we are confident that we are on the path to profitability.

Technologies and trends such as artificial intelligence, big-data, and combining genomic and immune-marker testing to improve patient outcomes and accelerate the discovery of new therapeutics are all areas that CGI is continuing to integrate into our business model and into our global business infrastructure. We believe our growing reach into the oncology ecosystem coupled with the strengthening of our operating fundamentals makes CGI a leader in developing and delivering oncology diagnostics from bench to bedside, concluded Sharma.

ABOUT CANCER GENETICS

Cancer Genetics, Inc. is an emerging leader in enabling precision medicine for oncology through the use of molecular markers and information. CGI is developing a global footprint with locations in the US, India and China. We have established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.

The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State.

For more information, please visit or follow us:

Internet:www.cancergenetics.com Twitter:@Cancer_Genetics Facebook:www.facebook.com/CancerGenetics

Forward Looking Statements:

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in revenues, margins, research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. tests and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements.

Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks that anticipated benefits from acquisitions will not be realized, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Cancer Genetics, Inc. Form 10-K for the year ended December 31, 2016 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics, Inc. disclaims any obligation to update these forward-looking statements.

Non-GAAP Financial Information

In addition to disclosing financial results in accordance with United States (U.S.) generally accepted accounting principles (GAAP), this earnings release contains non-GAAP financial measures that we believe are helpful in understanding and comparing our past financial performance and our future results. The non-GAAP financial measures disclosed by the Company exclude the non- operating changes in the fair value of derivative instruments. These non-GAAP financial measures should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations from these results should be carefully evaluated. Management believes that these non-GAAP measures provide useful information about the Company's core operating results and thus are appropriate to enhance the overall understanding of the Company's past financial performance and its prospects for the future. The non-GAAP financial measures in this press release include Adjusted Net (Loss) and the related adjusted basic and diluted per share amounts.

Reconciliation from GAAP to Non-GAAP Results (in thousands, except per share amounts):

Human Life Could Be Extended Indefinitely, Study Suggests

Goosebumps, tears and tenderness: what it means to be moved

Are over-the-counter painkillers a waste of money?

Does an anomaly in the Earth's magnetic field portend a coming pole reversal?

Immunotherapy: Training the body to fight cancer

Do vegetarians live longer? Probably, but not because they're vegetarian

Could a contraceptive app be as good as the pill?

Some scientific explanations for alien abduction that aren't so out of this world

Society actually does want policies that benefit future generations

Six cosmic catastrophes that could wipe out life on Earth

Big Pharma Starts Using Cannabis For Making Drugs In Earnest

Do you need to worry if your baby has a flat head?

Read the original post:
Cancer Genetics, Inc. Announces 15% Revenue Increase in First ... - EconoTimes

May 11, 2017 Japanese scientist have isolated and characterized a protein in chloroplasts that is essential for proper nucleoid segregation. Credit: Kyoto University

Proper DNA inheritance is essential for healthy cell growth and division. The same goes for the genetic material found in chloroplasts: the energy centers of all plant cells.

Chloroplast genomeslikely vestiges of ancestral bacteriaare organized into DNA-protein complexes called nucleoids. While significant work has been done to understand the dynamics of DNA in the nuclei of plant cells, little is known about the dynamics of chloroplast nucleoids.

Now Yusuke Kobayashi and Yoshiki Nishimura of Kyoto University, Osami Misumi of Yamaguchi University, and other collaborators have isolated and characterized a protein in chloroplasts that is essential for proper nucleoid segregation. Their findings were published recently in the journal Science.

"To understand the dynamics of chloroplast nucleoids, we focused on their behavior during chloroplast division in the green alga Chlamydomonas reinhardtii," explains Nishimura.

"We screened about 6,000 specimens with random mutations in their DNA and then isolated the ones with defective nucleoid segregation."

One of these mutants was found to have a defect in a gene the team calls moc1, for "Monokaryotic Chloroplast 1". The chloroplasts in this mutant possessed only a single nucleoid, and showed unequal segregation during chloroplast division. A homologous moc1 gene was then found in a land plant commonly used for research, Arabidopsis thaliana. When mutated, the researchers discovered that these organisms exhibit growth defects and abnormal nucleoid segregation.

After extensive analysis of this new gene, the team discovered that moc1 functions as a chloroplast-specific 'Holliday junction resolvase', which Nishimura continues, "is very important in untangling a DNA structure called Holliday junctions. These genes have never been found in chloroplasts, until now."

Continuing with their study, the researchers successfully visualized the activity of moc1 on Holliday junctions through the use of high-speed atomic force microscopy and DNA origami technology. They observed moc1 binding to the core of Holliday junctions and cutting them symmetrically.

The team's discovery improves understanding of the highly complex structures maintaining chloroplast DNA, whose proper functioning is essential for good cell health.

Explore further: A mutation giving leaves with white spots has been identified

More information: "Holliday junction resolvases mediate chloroplast nucleoid segregation" Science (2017). science.sciencemag.org/cgi/doi/10.1126/science.aan0038

Journal reference: Science

Provided by: Kyoto University

Garden and potted plants with white spots on their leaves are so popular that they are specially selected for this feature. An international research team has now identified a new mutation in the plant Lotus japonicus which ...

Researchers of Kumamoto University in Japan have succeeded in the world's first visualization of a peptidoglycan 'wall' present in the chloroplasts of bryophytes (moss plants). Until now, chloroplasts of green plants were ...

Researchers at Ruhr-Universitt Bochum have analysed how green algae manufacture complex components of a hydrogen-producing enzyme. The enzyme, known as the hydrogenase, may be relevant for the biotechnological production ...

Researchers at Tohoku University have identified a previously uncharacterized type of autophagy, during which an autophagic process termed chlorophagy removes collapsed chloroplasts in plant leaves. The findings could lead ...

Green algae and higher plants both harbor specialized cell organelles the chloroplasts in which photosynthesis takes place. This process allows these organisms to utilize energy from sunlight to power their biochemical ...

The discovery of a new gene is helping researchers at Michigan State University envision more-efficient molecular factories of the future.

University of Dundee scientists have solved a mystery concerning one of the most fundamental processes in cell biology, in a new discovery that they hope may help to tackle cancer one day.

Leading hospital "superbugs," known as the enterococci, arose from an ancestor that dates back 450 million yearsabout the time when animals were first crawling onto land (and well before the age of dinosaurs), according ...

A recent research paper in the Journal of Heredity reveals that there are three sub-species of snow leopard. Until now, researchers had assumed this species, Panthera uncia, was monotypic.

Adult stem cells have the ability to transform into many types of cells, but tracing the path individual stem cells follow as they mature and identifying the molecules that trigger these fateful decisions are difficult in ...

In their quest to replicate themselves, viruses have gotten awfully good at tricking human cells into pumping out viral proteins. That's why scientists have been working to use viruses as forces for good: to deliver useful ...

A UCLA study has found that a common strain of Caenorhabditis elegansa type of roundworm frequently used in laboratory research on neural developmenthas a pair of genes that encode both a poison and its antidote. The ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Go here to read the rest:
Disentangling chloroplast genetics: Scientists isolate a critical gene ... - Phys.Org

UPDATE 1-US Homeland Security: No announcement Friday on laptop ban expansion

WASHINGTON, May 12 U.S. Department of Homeland Security Secretary John Kelly is speaking with European officials on Friday to discuss threats to aviation and a possible expansion of a ban on in-cabin electronics larger than cellphones, U.S. and European officials said Friday.

View original post here:
BRIEF-CANCER GENETICS INC REPORTS Q1 LOSS PER SHARE $0.51 - Reuters

The other day a patient came to see me concerned that every time he drank coffee, his heart seemed to twitch. Is this cardiac twitch a sign of heart disease? he asked. A doctor himself, he pointed to a study done in Zurich that suggested that drinking the equivalent of two cups of coffee reduced the bodys ability to boost blood flow to the heart muscle in response to exercise and that this caffeine effect was stronger at high altitudes. That got me a bit worried myself. Like many of us, I fancy myself an amateur barista. So how much should we be having?

When it comes down to it, the main active ingredient in coffee is caffeine. Caffeine is a plant alkaloid that occurs naturally in coffee, tea, guarana and kola nuts. Its considered the most widely used drug in the world. The good news is that caffeine improves lung function, helps glucose metabolism in the gut, aids athletic performance, and is used in medications for ailments like migraines. Many carbonated drinks also contain caffeine and when present, manufacturers automatically increase sugar content, as caffeine dulls sugar taste receptors. This increased sugar is what makes soda especially bad for you.

We metabolize caffeine at different speeds

It turns out that your cardiac twitch is related to your caffeine metabolism slow metabolizers of caffeine have a higher risk of heart attacks if they drink more than two cups of coffee per day; however, fast metabolizers have a reduced risk of a heart attack if they have at least a cup of coffee a day. I suggested that I run some genetic tests on my patient (and while I was at it, I thought Id test myself). Knowing your genetic type is important here, as when it comes to CYP1A2 and coffee, there are some interesting facts.

Those of us with the AA variant of the CYP1A2 gene are fast metabolizers, while those with the AC or CC subtypes of the gene are slow metabolizers. The risky ones are the GA or AA variants. My risk was not elevated, even if (in general) its best to limit caffeine to 300 to 400 milligrams each day. However, my patient had the GA variant, meaning that, if he drinks more than 200 milligrams of caffeine a day, his heart disease could end up being more than just a twitch.

The main varieties of coffee bean are Arabica or Robusta and the latter has twice the caffeine content. So how much caffeine does a cup of coffee have per cup? The results may surprise you:

Understanding your gene type and how much caffeine is in your favorite drink is important to make sure youre living your healthiest life especially if you love your coffee, as your genes may have other ideas for you.

Read more:
Genetics determine how much coffee you can drink before it goes wrong - New York Post

AgReliant Genetics is the third largest corn seed company.

Darrell Smith

TAGS: Marketing, Overseas

December 18, 2014

Starting in 2018, AgReliant Genetics will go from eight representative brands to fourtransitioning half of their brands into LG Seeds. AgReliant says this is part of a growth initiative. AgriGold brand in the U.S. and Pride Seeds in Canada will continue as they are today.

Seed brands going to merge into LG Seeds include: Golden Acres Genetics, Great Lakes Hybrids, Producers Hybrids and Wensman Seed. The company says it will combine the best practices of each brand while maintaining its current employees, facilities and existing relationships.

AgReliant is currently the third largest corn seed company in North Americathe company aims to support its current position while reaching for higher accolades.

The adoption of new technologies, the speed of innovation and farmers growing demand for instant access to information are shifting how we do business, says Mark Herrman, AgReliant Genetics president and CEO in a recent press release. For this reason, we are committed to a strategic long-range plan that will extend our continuous growth and position us to better serve farm businesses and seed dealers in this dynamic environment.

Originally posted here:
AgReliant Genetics Restructures Seed Brands - AgWeb

Direct-to-consumer (DTC) genetics company 23andMe was recently granted approval by the Food and Drug

To continue reading this article and to access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space you need to be logged into the site and have an active subscription or trial subscription. Please loginorsubscribe in order to continue reading. Claim a week's trial subscriptionby signing up for free today and receive our daily pharma and biotech news bulletin free of charge, forever.

23andMeColor GenomicsDNA4LifeFDA blogFocus OnGeneticsRegulationUS FDAUSA

Access The Pharma Letter's latest news free for 7 days

PLUS... you can receive the Pharma Letter headlines and news roundup email free forever

Click here to take a free trial

Unlimited access to The Pharma Letter site for a whole year Only 77 per month or 820 per year

Click here to subscribe

See more here:
Direct-to-consumer genetics a new era in personalized medicine? - The Pharma Letter (registration)

The coffin of a little girl was found buried beneath a San Francisco home during renovation work in 2016. (Photo courtesy of Garden of Innocence)

Richard E. (Ed) Green, associate professor of biomolecular engineering, helped identify the remains. (Photo by C. Lagattuta)

On May 9, 2016, a contractor discovered the casket of a child while excavating the backyard of the Karner family in the Lone Mountain neighborhood of San Francisco, setting off a search for the child's identity that garnered international attention.

It was determined that the lost child was a little girl, approximately 2 to 3 years of age, but who was she? What happened to her? When UC Davis anthropology professor Jelmer Eerkens heard about the little girldubbed Miranda Evehe knew he had to help.

I read they were planning to just rebury the body without any analysis, Eerkens told the New York Times in June. As an archaeologist, I thought, thats not right. At some point, these things from the past become our collective heritage.

To unravel the mystery, Eerkens worked with more than 30 specialists and volunteers, including UC Santa Cruz biomolecular engineering professor Ed Green and genealogist and Garden of Innocence founder Elissa Davey. Green's DNA analysis ultimately enabled the investigators to make a definite identification of the child in the casket.

The type of casket Miranda Eve was found in, along with the clothes she was wearing, indicated she was buried approximately 140 to 150 years ago. Researchers discovered that from 1865 until the early 20th century, the present day Lone Mountain neighborhood of San Francisco had been a cemetery owned by the Independent Order of Odd Fellows. The cemetery closed to new burials in 1902, and in the early 1930s, those interred there were removed and reburied in the Greenlawn Cemetery in Colma, Calif. Somehow, the little girl's casket was missed and left behind.

Historical maps

Using an 1865 plan for the development of the cemetery (a map for a time after 1902 could not be located), researchers pinpointed two sections of the cemetery that most likely intersected with the location of the Karners home. Historical maps were then digitally layered on top of each other and cross-referenced against photographs to identify any family plots in that location.

Before she was reinterred, samples of hair were taken for chemical and DNA testing in the hopes of finding a match with a living relative and learning what led to her death at such a young age. In the clean-room facilities in Green's Paleogenomics lab at UC Santa Cruz, DNA was extracted from the Miranda Eve hair samples using standard ancient DNA techniques.

Meanwhile, Eerkens and his students at UC Davis analyzed the nitrogen isotopes in the hair, which revealed that she had suffered from malnourishment for several months before her death. This indicates she was suffering from a chronic illness that caused wasting or starvation, rather than something more sudden such as smallpox, which was common during this time, or an injury, he said. While the exact illness is still unknown, we suspect an illness caused her to eat less and less until she was unable to eat at all.

DNA analysis

Green's initial analysis of the nuclear DNA confirmed little Miranda Eve to be a girl of likely European ancestry, and her mitochondrial DNA was found to be a type most common on the British Isles.

Research on internment records narrowed the search to two highly likely candidates for Miranda Eve's true identity, and an exhaustive search of genealogical records eventually found living family descendants for both candidates. The descendants were contacted and agreed to provide DNA samples for comparison. Green then was able to find a clear match between the DNA from the hair sample and that obtained from the living family member of one of the candidates.

After a year-long search, the mystery was solved: Miranda Eve was born on November 28, 1873, as Edith Howard Cook, the eldest daughter of Horatio Nelson and Edith Scooffy Cook, members of two prominent San Francisco families during the late 19th and early 20th centuries. Edith died just short of her third birthday in October 1876. Her three siblings, two brothers and a sister, survived her. Her older brother Milton H. Cooks grandson, Peter Cook, resides in the San Francisco Bay Area today.

Peter Cooks father passed away when he was just three years old, so he didnt know much about his fathers family history until Eerkens contacted him about Edith. When the DNA testing came back as a match, It hit the roof for me. I was beaming ear-to-ear with the news, Cook said. Now the 82-year-old can share the Cook family history with his eight children, 13 grandchildren, and 10 great-grandchildren.

Principle researchers on this project in addition to Professors Eerkens and Green and Ms. Davey, include Dave Frederick, genealogist and cold case investigator based in Billings, Mt., genealogist Bob Phillips of Seattle, Wa., and Alex Snyder, transportation planner and public historian in San Francisco.

Link:
UC Santa Cruz genetics lab helps solve the mystery of 'Miranda Eve' - UC Santa Cruz (press release)

UPDATE 2-Brazil inflation hits lowest in nearly 10 years in April

(Adds data, market reaction, economist's comment) By Silvio Cascione BRASILIA, May 10 Brazil's annual inflation rate fell in April to its lowest level in nearly 10 years, bolstering the view of a steep interest rate cut by the central bank at the end of this month. Consumer prices rose 4.08 percent in the 12 months through April, slightly below market forecasts for a 4.10 percent increase and compared with an increase of 4.57 percent in the year to March, the national st

Here is the original post:
BRIEF-Atossa Genetics says second positive interim review on Phase 1 study of endoxifen may advance to final topical ... - Reuters